Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation

Jason D. Roberts, Thomas Dewland, David V. Glidden, Thomas J. Hoffmann, Dan E. Arking, Lin Y. Chen, Bruce M. Psaty, Jeffrey E. Olgin, Alvaro Alonso, Susan R. Heckbert, Gregory M. Marcus

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting. Recent genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with AF, potentially identifying clinically relevant subtypes of the disease. We sought to investigate the impact of carrier status of 9 AF-associated SNPs on the efficacy of RAS inhibition for the primary prevention of AF. Methods We performed SNP-RAS inhibitor interaction testing with unadjusted and adjusted Cox proportional hazards models using a discovery (Cardiovascular Health Study) and a replication (Atherosclerosis Risk in Communities) cohort. Additive genetic models were used for the SNP analyses, and 2-tailed P values

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalAmerican Heart Journal
Volume175
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Renin-Angiotensin System
Atrial Fibrillation
Single Nucleotide Polymorphism
Angiotensin Receptor Antagonists
Genome-Wide Association Study
Genetic Models
Primary Prevention
Proportional Hazards Models
Angiotensin-Converting Enzyme Inhibitors
Atherosclerosis
Health
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. / Roberts, Jason D.; Dewland, Thomas; Glidden, David V.; Hoffmann, Thomas J.; Arking, Dan E.; Chen, Lin Y.; Psaty, Bruce M.; Olgin, Jeffrey E.; Alonso, Alvaro; Heckbert, Susan R.; Marcus, Gregory M.

In: American Heart Journal, Vol. 175, 01.05.2016, p. 9-17.

Research output: Contribution to journalArticle

Roberts, JD, Dewland, T, Glidden, DV, Hoffmann, TJ, Arking, DE, Chen, LY, Psaty, BM, Olgin, JE, Alonso, A, Heckbert, SR & Marcus, GM 2016, 'Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation', American Heart Journal, vol. 175, pp. 9-17. https://doi.org/10.1016/j.ahj.2016.02.002
Roberts, Jason D. ; Dewland, Thomas ; Glidden, David V. ; Hoffmann, Thomas J. ; Arking, Dan E. ; Chen, Lin Y. ; Psaty, Bruce M. ; Olgin, Jeffrey E. ; Alonso, Alvaro ; Heckbert, Susan R. ; Marcus, Gregory M. / Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. In: American Heart Journal. 2016 ; Vol. 175. pp. 9-17.
@article{736dd67a4dd548fa845913704b545d7f,
title = "Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation",
abstract = "Background Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting. Recent genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with AF, potentially identifying clinically relevant subtypes of the disease. We sought to investigate the impact of carrier status of 9 AF-associated SNPs on the efficacy of RAS inhibition for the primary prevention of AF. Methods We performed SNP-RAS inhibitor interaction testing with unadjusted and adjusted Cox proportional hazards models using a discovery (Cardiovascular Health Study) and a replication (Atherosclerosis Risk in Communities) cohort. Additive genetic models were used for the SNP analyses, and 2-tailed P values",
author = "Roberts, {Jason D.} and Thomas Dewland and Glidden, {David V.} and Hoffmann, {Thomas J.} and Arking, {Dan E.} and Chen, {Lin Y.} and Psaty, {Bruce M.} and Olgin, {Jeffrey E.} and Alvaro Alonso and Heckbert, {Susan R.} and Marcus, {Gregory M.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.ahj.2016.02.002",
language = "English (US)",
volume = "175",
pages = "9--17",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation

AU - Roberts, Jason D.

AU - Dewland, Thomas

AU - Glidden, David V.

AU - Hoffmann, Thomas J.

AU - Arking, Dan E.

AU - Chen, Lin Y.

AU - Psaty, Bruce M.

AU - Olgin, Jeffrey E.

AU - Alonso, Alvaro

AU - Heckbert, Susan R.

AU - Marcus, Gregory M.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting. Recent genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with AF, potentially identifying clinically relevant subtypes of the disease. We sought to investigate the impact of carrier status of 9 AF-associated SNPs on the efficacy of RAS inhibition for the primary prevention of AF. Methods We performed SNP-RAS inhibitor interaction testing with unadjusted and adjusted Cox proportional hazards models using a discovery (Cardiovascular Health Study) and a replication (Atherosclerosis Risk in Communities) cohort. Additive genetic models were used for the SNP analyses, and 2-tailed P values

AB - Background Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting. Recent genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with AF, potentially identifying clinically relevant subtypes of the disease. We sought to investigate the impact of carrier status of 9 AF-associated SNPs on the efficacy of RAS inhibition for the primary prevention of AF. Methods We performed SNP-RAS inhibitor interaction testing with unadjusted and adjusted Cox proportional hazards models using a discovery (Cardiovascular Health Study) and a replication (Atherosclerosis Risk in Communities) cohort. Additive genetic models were used for the SNP analyses, and 2-tailed P values

UR - http://www.scopus.com/inward/record.url?scp=84960117960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960117960&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2016.02.002

DO - 10.1016/j.ahj.2016.02.002

M3 - Article

C2 - 27179719

AN - SCOPUS:84960117960

VL - 175

SP - 9

EP - 17

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -